Skip to main content
Fig. 3 | BMC Women's Health

Fig. 3

From: Relugolix for oral treatment of uterine leiomyomas: a dose-finding, randomized, controlled trial

Fig. 3

Primary efficacy endpoint: proportion of patients with a total pictorial blood loss assessment chart (PBAC) score < 10 at weeks 6–12. Error bars show 95% confidence intervals for differences vs. placebo. ***P < .001. Note: Differences were analyzed between each relugolix group and placebo group using chi-square tests according to the closed testing procedure, initially from the relugolix 40-mg group vs. the placebo group, to control the type I error rates in multiple comparison

Back to article page